With the approval of RPE65 gene therapy and the increased number of inherited retinal disease patients undergoing DNA sequencing, there is an increasing need for higher throughput pathogenicity assays for RPE65 variants. This evidence concerns the gene RPE65 and Abnormal retinal morphology.